{
    "clinical_study": {
        "@rank": "55397", 
        "arm_group": [
            {
                "arm_group_label": "Carfilzomib Combination", 
                "arm_group_type": "Experimental", 
                "description": "Carfilzomib (3 + 3 dose escalation scheme: Days 2, 3, 9, 10 of each 21-day cycle) + Carboplatin (target AUC = 5: Day 1 of each 21-day cycle) + Etoposide (100 mg/m2: Days 1, 2, 3 of each 21-day cycle)"
            }, 
            {
                "arm_group_label": "Control Arm", 
                "arm_group_type": "Active Comparator", 
                "description": "Carboplatin (target AUC = 5: Day 1 of each 21-day cycle) + Etoposide (100 mg/m2: Days 1, 2, 3 of each 21 -day cycle)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the maximum tolerated dose and assess the safety,\n      tolerability and activity of carfilzomib given in combination with carboplatin and etoposide\n      as initial therapy for subjects with Extensive-Stage Small-Cell Lung Cancer (ES SCLC)."
        }, 
        "brief_title": "Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Subjects With Previously Untreated Extensive Stage Small-cell Lung Cancer", 
        "completion_date": {
            "#text": "September 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Extensive-Stage Small-Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Lung Neoplasms", 
                "Small Cell Lung Carcinoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          1. Histologically or cytologically confirmed diagnosis of extensive-stage small-cell\n             lung cancer (ES-SCLC) with measurable disease per Response Evaluation Criteria in\n             Solid Tumors (RECIST) Version 1.1; ES-SCLC is defined as:  small-cell lung cancer\n             (SCLC) that has spread beyond one hemithorax and regional lymph nodes on the same\n             side (e.g., supraclavicular) to the contralateral hemithorax, lymph nodes, or more\n             distant locations in the body\n\n          2. Subjects with asymptomatic brain metastases or other central nervous system (CNS)\n             disease at screening/diagnosis are eligible\n\n          3. Males and females \u2265 18 years of age\n\n          4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n\n        Key Exclusion Criteria:\n\n          1. Previous systemic therapy to treat small-cell lung cancer (SCLC).  Subjects with\n             recurrent or progressive limited-stage SCLC after previous systemic treatment are not\n             eligible for study participation.\n\n          2. Whole brain or focal radiation therapy within 14 days prior to Cycle 1 Day 1 (C1D1)\n             for Phase 1b or prior to randomization for Phase 2\n\n          3. Congestive heart failure (New York Heart Association [NYHA] class III to IV),\n             symptomatic ischemia, conduction abnormalities uncontrolled by conventional\n             intervention, or myocardial infarction within 6 months prior to prior to C1D1 for\n             Phase 1b or prior to randomization for Phase 2"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01987232", 
            "org_study_id": "CFZ004", 
            "secondary_id": "2013-002597-44"
        }, 
        "intervention": [
            {
                "arm_group_label": "Carfilzomib Combination", 
                "intervention_name": "Carfilzomib", 
                "intervention_type": "Drug", 
                "other_name": [
                    "PR-171", 
                    "PR171", 
                    "Kyprolis\u00ae (carfilzomib) for Injection"
                ]
            }, 
            {
                "arm_group_label": [
                    "Carfilzomib Combination", 
                    "Control Arm"
                ], 
                "intervention_name": "Carboplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Carfilzomib Combination", 
                    "Control Arm"
                ], 
                "intervention_name": "Etoposide", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Etoposide", 
                "Etoposide phosphate", 
                "Carboplatin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut"
                    }, 
                    "name": "Yale University, Yale Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Goshen", 
                        "country": "United States", 
                        "state": "Indiana"
                    }, 
                    "name": "Goshen Center for Cancer Care"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lafayette", 
                        "country": "United States", 
                        "state": "Indiana"
                    }, 
                    "name": "Horizon Oncology Research, Inc."
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Muncie", 
                        "country": "United States", 
                        "state": "Indiana"
                    }, 
                    "name": "Indiana University Health Ball Memorial Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lexington", 
                        "country": "United States", 
                        "state": "Kentucky"
                    }, 
                    "name": "Baptist Health Lexington Clinical Research Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frederick", 
                        "country": "United States", 
                        "state": "Maryland"
                    }, 
                    "name": "Frederick Memorial Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hackensack", 
                        "country": "United States", 
                        "state": "New Jersey"
                    }, 
                    "name": "John Theurer Cancer Center at Hackensack UMC"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charlotte", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }, 
                    "name": "Levine Cancer Institute"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 1b/2, Multicenter, Open-label Study of Carfilzomib, Carboplatin, and Etoposide in Subjects With Previously Untreated Extensive-stage Small-cell Lung Cancer", 
        "overall_contact": {
            "email": "medinfo@onyx.com", 
            "last_name": "Onyx Medical Information", 
            "phone": "1-877-669-9121"
        }, 
        "overall_official": {
            "affiliation": "Onyx Therapeutics, Inc.", 
            "last_name": "Paula O'Connor, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "European Union: European Medicines Agency", 
                "Russia: Ministry of Health of the Russian Federation", 
                "Canada: Health Canada", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Ukraine: Ministry of Health", 
                "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "To determine the MTD of carfilzomib given in combination with standard dose carboplatin (target AUC = 5; IV) on Day 1 and etoposide (100 mg/m2; IV) on Days 1, 2, and 3 every 3 weeks as treatment for previously untreated Extensive-stage Small-cell Lung Cancer (ES-SCLC). The MTD is defined as the highest dose level at which < 33% of subjects experience a dose-limiting toxicity (DLT) during the first 21-day cycle.", 
                "measure": "Maximum Tolerated Dose (MTD) - Phase 1b", 
                "safety_issue": "Yes", 
                "time_frame": "First 21-day Cycle"
            }, 
            {
                "description": "To evaluate the efficacy of carfilzomib with carboplatin and etoposide (carfilzomib combination arm) versus carboplatin and etoposide alone (control arm) in subjects with treatment-na\u00efve ES-SCLC, as measured by progression-free survival (PFS).", 
                "measure": "Progression-free Survival (PFS) - Phase 2", 
                "safety_issue": "No", 
                "time_frame": "24 months after the first subject is randomized"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01987232"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Best Overall Response (BOR) is defined as either confirmed complete response (CR) or partial response (PR) per RECIST Version 1.1.", 
                "measure": "Best Overall Response (BOR) - Phase 1b & Phase 2", 
                "safety_issue": "No", 
                "time_frame": "24 months after the first subject is randomized"
            }, 
            {
                "description": "Duration of Response (DOR) is defined as the time from first evidence of partial response (PR) or better to documented progressive disease (PD) or death due to any cause.", 
                "measure": "Duration of Response (DOR) - Phase 1b & Phase 2", 
                "safety_issue": "No", 
                "time_frame": "24 months after the first subject is randomized"
            }, 
            {
                "description": "Overall Survival (OS) is defined as the time from randomization to the date of death.", 
                "measure": "Overall Survival (OS) - Phase 2", 
                "safety_issue": "No", 
                "time_frame": "30 months after the first subject is randomized"
            }, 
            {
                "description": "Number of patients that experience Adverse Events (AEs)", 
                "measure": "Adverse Events - Phase 1b & Phase 2", 
                "safety_issue": "Yes", 
                "time_frame": "24 months after the first subject is randomized"
            }, 
            {
                "description": "Maximum plasma concentration (Cmax, observed)", 
                "measure": "Maximum Plasma Concentration - Phase 2", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1 Day 2"
            }, 
            {
                "description": "Time of maximum plasma concentration (Tmax, observed)", 
                "measure": "Time of Maximum Plasma Concentration - Phase 2", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1 Day 2"
            }, 
            {
                "description": "Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration and to infinity (AUC0-last and AUC0-\u221e)", 
                "measure": "Area Under Plasma Concentration-Time Curve - Phase 2", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1 Day 2"
            }
        ], 
        "source": "Onyx Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Onyx Therapeutics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}